Search

Your search keyword '"Kirson, Eilon"' showing total 262 results
Start Over "Kirson, Eilon"
262 results on '"Kirson, Eilon"'

1. Investigating the Connection Between Tumor-Treating Fields Distribution in the Brain and Glioblastoma Patient Outcomes. A Simulation-Based Study Utilizing a Novel Model Creation Technique

Author

Urman, Noa, Levy, Shay, Frenkel, Avital, Manzur, Doron, Hershkovich, Hadas Sara, Naveh, Ariel, Yesharim, Ofir, Wenger, Cornelia, Lavy-Shahaf, Gitit, Kirson, Eilon, Bomzon, Ze’ev, Makarov, Sergey, editor, Horner, Marc, editor, and Noetscher, Gregory, editor

Published
2019
Full Text
View/download PDF

4. Effect of Tumor-Treating Fields Plus Maintenance Temozolomide vs Maintenance Temozolomide Alone on Survival in Patients With Glioblastoma: A Randomized Clinical Trial

Author

Stupp, Roger, Taillibert, Sophie, Kanner, Andrew, Read, William, Steinberg, David M., Lhermitte, Benoit, Toms, Steven, Idbaih, Ahmed, Ahluwalia, Manmeet S., Fink, Karen, Di Meco, Francesco, Lieberman, Frank, Zhu, Jay-Jiguang, Stragliotto, Giuseppe, Tran, David D., Brem, Steven, Hottinger, Andreas F., Kirson, Eilon D., Lavy-Shahaf, Gitit, Weinberg, Uri, Kim, Chae-Yong, Paek, Sun-Ha, Nicholas, Garth, Burna, Jordi, Hirte, Hal, Weller, Michael, Palti, Yoram, Hegi, Monika E., and Ram, Zvi

Published
2017
Full Text
View/download PDF

5. NovoTTF-100A versus physician’s choice chemotherapy in recurrent glioblastoma: A randomised phase III trial of a novel treatment modality

Author

Stupp, Roger, Wong, Eric T., Kanner, Andrew A., Steinberg, David, Engelhard, Herbert, Heidecke, Volkmar, Kirson, Eilon D., Taillibert, Sophie, Liebermann, Frank, Dbalý, Vladimir, Ram, Zvi, Villano, J. Lee, Rainov, Nikolai, Weinberg, Uri, Schiff, David, Kunschner, Lara, Raizer, Jeffrey, Honnorat, Jerome, Sloan, Andrew, Malkin, Mark, Landolfi, Joseph C., Payer, Franz, Mehdorn, Maximilian, Weil, Robert J., Pannullo, Susan C., Westphal, Manfred, Smrcka, Martin, Chin, Lawrence, Kostron, Herwig, Hofer, Silvia, Bruce, Jeffrey, Cosgrove, Rees, Paleologous, Nina, Palti, Yoram, and Gutin, Philip H.

Published
2012
Full Text
View/download PDF

7. Maintenance Therapy With Tumor-Treating Fields Plus Temozolomide vs Temozolomide Alone for Glioblastoma: A Randomized Clinical Trial

Author

Stupp, Roger, Taillibert, Sophie, Kanner, Andrew A., Kesari, Santosh, Steinberg, David M., Toms, Steven A., Taylor, Lynne P., Lieberman, Frank, Silvani, Antonio, Fink, Karen L., Barnett, Gene H., Zhu, Jay-Jiguang, Henson, John W., Engelhard, Herbert H., Chen, Thomas C., Tran, David D., Sroubek, Jan, Tran, Nam D., Hottinger, Andreas F., Landolfi, Joseph, Desai, Rajiv, Caroli, Manuela, Kew, Yvonne, Honnorat, Jerome, Idbaih, Ahmed, Kirson, Eilon D., Weinberg, Uri, Palti, Yoram, Hegi, Monika E., and Ram, Zvi

Published
2015
Full Text
View/download PDF

9. Abstract 2411: Cancer cell lines meta-analysis according to both short-term and long-term responses to Tumor Treating Fields (TTFields)

Author

Katsir, Kerem Wainer, primary, Shahaf, Gitit Lavy, additional, Giladi, Moshe, additional, Schneiderman, Rosa S., additional, Urman, Noa, additional, Gotlieb, Karnit, additional, Zeevi, Einav, additional, Porat, Yaara, additional, Munster, Mijal, additional, Kinzel, Adrian, additional, Weinberg, Uri, additional, Kirson, Eilon D., additional, and Palti, Yoram, additional

Published
2020
Full Text
View/download PDF

10. Abstract B14: Immunomodulatory effect of tumor treating fields (TTFields) results in enhanced antitumor efficacy when combined with anti-PD-1 therapy

Author

Voloshin, Tali, primary, Davidi, Shiri, additional, Porat, Yaara, additional, Shteingauz, Anna, additional, Munster, Mijal, additional, Kaynan, Noa, additional, Schneiderman, Rosa S, additional, Brami, Catherine Tempel, additional, Alon, Yaniv, additional, Zeevi, Einav, additional, Gotlib, Karnit, additional, Blat, Roni, additional, Cahal, Shay, additional, Itzhaki, Aviran, additional, Giladi, Moshe, additional, Kirson, Eilon D., additional, Weinberg, Uri, additional, Kinzel, Adrian, additional, and Palti, Yoram, additional

Published
2020
Full Text
View/download PDF

11. In vitro and in vivo efficacy and safety of tumor treating fields (TTFields) and sorafenib combination in hepatocellular carcinoma.

Author

Davidi, Shiri, primary, Tempel-Brami, Catherine, additional, Munster, Mijal, additional, Gotlib, Karnit, additional, Zeevi, Einav, additional, Schneiderman, Rosa S, additional, Voloshin, Tali, additional, Giladi, Moshe, additional, Kinzel, Adrian, additional, Kirson, Eilon D., additional, Weinberg, Uri, additional, and Palti, Yoram, additional

Published
2020
Full Text
View/download PDF

12. Tumor treating fields (TTFields; 150 kHz) and FOLFOX combination treatment effects on gastric cancer in vitro.

Author

Zeevi, Einav, primary, Gotlib, Karnit, additional, Schneiderman, Rosa S, additional, Munster, Mijal, additional, Porat, Yaara, additional, Voloshin, Tali, additional, Davidi, Shiri, additional, Shteingauz, Anna, additional, Kaynan, Noa, additional, Giladi, Moshe, additional, Kirson, Eilon D., additional, Weinberg, Uri, additional, Kinzel, Adrian, additional, and Palti, Yoram, additional

Published
2020
Full Text
View/download PDF

13. Immunomodulatory effects of tumor treating fields (TTFields) on colon cancer models.

Author

Voloshin, Tali, primary, Kaynan, Noa, additional, Davidi, Shiri, additional, Porat, Yaara, additional, Shteingauz, Anna, additional, Munster, Mijal, additional, Schneiderman, Rosa S, additional, Tempel-Brami, Catherine, additional, Zeevi, Einav, additional, Gotlib, Karnit, additional, Cahal, Shay, additional, Giladi, Moshe, additional, Kirson, Eilon D., additional, Weinberg, Uri, additional, Kinzel, Adrian, additional, and Palti, Yoram, additional

Published
2020
Full Text
View/download PDF

14. Effect of Tumor-Treating Fields Plus Maintenance Temozolomide vs Maintenance Temozolomide Alone on Survival in Patients With Glioblastoma

Author

Stupp, Roger, Taillibert, Sophie, Kanner, Andrew, Read, William, Steinberg, David M, Lhermitte, Benoit, Toms, Steven, Idbaih, Ahmed, Ahluwalia, Manmeet S, Fink, Karen, Di Meco, Francesco, Lieberman, Frank, Zhu, Jay-Jiguang, Stragliotto, Giuseppe, Tran, David D, Brem, Steven, Hottinger, Andreas F, Kirson, Eilon D, Lavy-Shahaf, Gitit, Weinberg, Uri, Kim, Chae-Yong, Paek, Sun-Ha, Nicholas, Garth, Burna, Jordi, Hirte, Hal, Weller, Michael, Palti, Yoram, Hegi, Monika E, Ram, Zvi, Stupp, Roger, Taillibert, Sophie, Kanner, Andrew, Read, William, Steinberg, David M, Lhermitte, Benoit, Toms, Steven, Idbaih, Ahmed, Ahluwalia, Manmeet S, Fink, Karen, Di Meco, Francesco, Lieberman, Frank, Zhu, Jay-Jiguang, Stragliotto, Giuseppe, Tran, David D, Brem, Steven, Hottinger, Andreas F, Kirson, Eilon D, Lavy-Shahaf, Gitit, Weinberg, Uri, Kim, Chae-Yong, Paek, Sun-Ha, Nicholas, Garth, Burna, Jordi, Hirte, Hal, Weller, Michael, Palti, Yoram, Hegi, Monika E, and Ram, Zvi

Published
2017

16. Die Wirkung von Tumortherapiefeldern auf die Zellmorphologie und Invasion verschiedener Tumorzellen

Author

Kinzel, Adrian, Schneiderman, Rosa, Giladi, Moshe, Zeevi, Einav, Shteingauz, Anna, Voloshin, Tali, Porat, Yaara, Munster, Mijal, Kirson, Eilon, and Palti, Yoram

Subjects
ddc: 610, 610 Medical sciences, Medicine
Abstract

Objective: Tumor Treating Fields (TTFields) therapy is indicated to treat glioblastoma multiforme. The treatment delivers low intensity, intermediate frequency alternating electric fields to the brain. In the past, the anti-mitotic effects of TTFields have been studied intensively to clarify the mechanism[for full text, please go to the a.m. URL], 70. Jahrestagung der Deutschen Gesellschaft für Neurochirurgie (DGNC), Joint Meeting mit der Skandinavischen Gesellschaft für Neurochirurgie

Published
2019
Full Text
View/download PDF

17. Supplementary_file_questionnaire – Supplemental material for Tumor Treating Fields for Glioblastoma Treatment: Patient Satisfaction and Compliance With the Second-Generation Optune® System

Author

Kinzel, Adrian, Ambrogi, Michael, Varshaver, Michael, and Kirson, Eilon D

Subjects
FOS: Clinical medicine, education, behavioral disciplines and activities, humanities, 111299 Oncology and Carcinogenesis not elsewhere classified
Abstract

Supplemental material, Supplementary_file_questionnaire for Tumor Treating Fields for Glioblastoma Treatment: Patient Satisfaction and Compliance With the Second-Generation Optune® System by Adrian Kinzel, Michael Ambrogi, Michael Varshaver and Eilon D Kirson in Clinical Medicine Insights: Oncology

Published
2019
Full Text
View/download PDF

19. Efficacy of Tumor Treating Fields (TTFields) and aurora B kinase inhibitor in glioma cells

Author

Krex, Dietmar, Temme, Achim, Schneidermann, Rosa, Giladi, Moshe, Kinzel, Adrian, Kirson, Eilon, and Palti, Yoram

Subjects
ddc: 610, 610 Medical sciences, Medicine
Abstract

Objective: Tumor Treating Fields (TTFields) are an effective anti-neoplastic treatment modality delivered via noninvasive application of low intensity, intermediate frequency, alternating electric fields. A promising approach to enhance the efficiency of TTFields is the use of drugs which extend metaphase-anaphase[for full text, please go to the a.m. URL], 69. Jahrestagung der Deutschen Gesellschaft für Neurochirurgie (DGNC), Joint Meeting mit der Mexikanischen und Kolumbianischen Gesellschaft für Neurochirurgie

Published
2018

21. Abstract 303: The efficacy of the combined treatment of 150 kHz Tumor Treating Fields (TTFields) and FOLFOX in gastric cancer in vitro

Author

Voloshin, Tali, primary, Zeevi, Einav, additional, Gotlib, Karnit, additional, Schneiderman, Rosa S., additional, Munster, Mijal, additional, Porat, Yaara, additional, Davidi, Shiri, additional, Shteingauz, Anna, additional, Kaynan, Noa, additional, Giladi, Moshe, additional, Kirson, Eilon D., additional, Weinberg, Uri, additional, Kinzel, Adrian, additional, and Palti, Yoram, additional

Published
2019
Full Text
View/download PDF

22. Abstract 3961: Alternating electric fields (TTFields) induce immunogenic cell death resulting in enhanced antitumor efficacy when combined with anti-PD-1 therapy

Author

Voloshin, Tali, primary, Kaynan, Noa, additional, Davidi, Shiri, additional, Porat, Yaara, additional, Shteingauz, Anna, additional, Munster, Mijal, additional, Schneiderman, Rosa S., additional, Brami, Catherine Tempel, additional, Zeevi, Einav, additional, Gotlib, Karnit, additional, Cahal, Shay, additional, Itzhaki, Aviran, additional, Giladi, Moshe, additional, Kirson, Eilon D., additional, Weinberg, Uri, additional, Kinzel, Adrian, additional, and Palti, Yoram, additional

Published
2019
Full Text
View/download PDF

27. Abstract 307: The combined treatment of 150 kHz Tumor Treating Fields (TTFields) and Cisplatin or Pemetrexed inhibit mesothelioma cells in vitro

Author

Munster, Mijal, primary, Schneiderman, Rosa, additional, Porat, Yaara, additional, Voloshin, Tali, additional, Davidi, Shiri, additional, Shteingauz, Anna, additional, Kaynan, Noa, additional, Zeevi, Einav, additional, Gotlib, Karnit, additional, Giladi, Moshe, additional, Kirson, Eilon, additional, Weinberg, Uri, additional, Kinzel, Adrian, additional, and Palti, Yoram, additional

Published
2019
Full Text
View/download PDF

30. Abstract 306: The efficacy of the combined treatment of 150 KHz tumor treating fields (TTFields) and Sorafenib in hepatocellular carcinoma in vitro and in vivo

Author

Voloshin, Tali, primary, Davidi, Shiri, additional, Tempel-Brami, Catherine, additional, Munster, Mijal, additional, Gotlib, Karnit, additional, Zeevi, Einav, additional, Schneiderman, Rosa S., additional, Giladi, Moshe, additional, Kinzel, Adrian, additional, Kirson, Eilon D., additional, Weinberg, Uri, additional, and Palti, Yoram, additional

Published
2019
Full Text
View/download PDF

31. The combined treatment of 150 kHz tumor treating fields (TTFields) and sorafenib inhibits hepatocellular carcinoma in vitro and in vivo.

Author

Weinberg, Uri, primary, Davidi, Shiri, additional, Tempel- Brami, Catherine, additional, Munster, Mijal, additional, Gotlib, Karnit, additional, Zeevi, Einav, additional, Schneiderman, Rosa S., additional, Voloshin, Tali, additional, Giladi, Moshe, additional, Kinzel, Adrian, additional, Kirson, Eilon David, additional, and Palti, Yoram, additional

Published
2019
Full Text
View/download PDF

32. The combined treatment of 150 kHz tumor treating fields (TTFields) and cisplatin or pemetrexed inhibits mesothelioma cells in vitro and in vivo.

Author

Weinberg, Uri, primary, Munster, Mijal, additional, Gotlib, Karnit, additional, Schneiderman, Rosa S., additional, Porat, Yaara, additional, Voloshin, Tali, additional, Davidi, Shiri, additional, Shteingauz, Anna, additional, Kaynan, Noa, additional, Zeevi, Einav, additional, Giladi, Moshe, additional, Kirson, Eilon David, additional, Kinzel, Adrian, additional, and Palti, Yoram, additional

Published
2019
Full Text
View/download PDF

35. In vitro and in vivo efficacy of the combined treatment of 150 khz tumor treating fields (TTFields) and sorafenib in hepatocellular carcinoma.

Author

Weinberg, Uri, primary, Davidi, Shiri, additional, Gotlib, Karnit, additional, Zeevi, Einav, additional, Tempel- Brami, Catherine, additional, Schneiderman, Rosa S., additional, Voloshin, Tali, additional, Giladi, Moshe, additional, Kinzel, Adrian, additional, Kirson, Eilon David, additional, and Palti, Yoram, additional

Published
2019
Full Text
View/download PDF

39. TTFields alone and in combination with chemotherapeutic agents effectively reduce the viability of MDR cell sub-lines that over-express ABC transporters

Author

Kirson Eilon D, Shmueli Esther, Schneiderman Rosa S, and Palti Yoram

Subjects
Neoplasms. Tumors. Oncology. Including cancer and carcinogens, RC254-282
Abstract

Abstract Background Exposure of cancer cells to chemotherapeutic agents may result in reduced sensitivity to structurally unrelated agents, a phenomenon known as multidrug resistance, MDR. The purpose of this study is to investigate cell growth inhibition of wild type and the corresponding MDR cells by Tumor Treating Fields - TTFields, a new cancer treatment modality that is free of systemic toxicity. The TTFields were applied alone and in combination with paclitaxel and doxorubicin. Methods Three pairs of wild type/MDR cell lines, having resistivity resulting from over-expression of ABC transporters, were studied: a clonal derivative (C11) of parental Chinese hamster ovary AA8 cells and their emetine-resistant sub-line EmtR1; human breast cancer cells MCF-7 and their mitoxantrone-resistant sub lines MCF-7/Mx and human breast cancer cells MDA-MB-231 and their doxorubicin resistant MDA-MB-231/Dox cells. TTFields were applied for 72 hours with and without the chemotherapeutic agents. The numbers of viable cells in the treated cultures and the untreated control groups were determined using the XTT assay. Student t-test was applied to asses the significance of the differences between results obtained for each of the three cell pairs. Results TTFields caused a similar reduction in the number of viable cells of wild type and MDR cells. Treatments by TTFields/drug combinations resulted in a similar increased reduction in cell survival of wild type and MDR cells. TTFields had no effect on intracellular doxorubicin accumulation in both wild type and MDR cells. Conclusions The results indicate that TTFields alone and in combination with paclitaxel and doxorubicin effectively reduce the viability of both wild type and MDR cell sub-lines and thus can potentially be used as an effective treatment of drug resistant tumors.

Published
2010
Full Text
View/download PDF

40. Additional file 3: Figure S2. of Tumor treating fields (TTFields) delay DNA damage repair following radiation treatment of glioma cells

Author

Giladi, Moshe, Mijal Munster, Schneiderman, Rosa, Voloshin, Tali, Porat, Yaara, Blat, Roni, Zielinska-Chomej, Katarzyna, Hååg, Petra, Ze’ev Bomzon, Kirson, Eilon, Weinberg, Uri, Viktorsson, Kristina, Lewensohn, Rolf, and Palti, Yoram

Abstract

TTFields Delay Irradiation-Induced DNA Damage Repair in glioma cells. LN-18 cells were irradiated with 4 Gy RT and immediately treated with TTFields applied for 1 h, 2 h or 24 h (A-B). Effect on DNA repair was measured as tail moment in the comet assay. (PPTX 1940 kb)

Published
2017
Full Text
View/download PDF

41. Additional file 1: Table S1. of Tumor treating fields (TTFields) delay DNA damage repair following radiation treatment of glioma cells

Author

Giladi, Moshe, Mijal Munster, Schneiderman, Rosa, Voloshin, Tali, Porat, Yaara, Blat, Roni, Zielinska-Chomej, Katarzyna, Hååg, Petra, Ze’ev Bomzon, Kirson, Eilon, Weinberg, Uri, Viktorsson, Kristina, Lewensohn, Rolf, and Palti, Yoram

Abstract

RT treatment schedule and transducer replacement schedule. Rats received RT on days 0-4 and 7-11 (indicated by V). Groups 4 and 5 had arrays placed on their dorsal surface (arrays where replaced days indicated by V). Rats where euthanized on day 12. (DOCX 96 kb)

Published
2017
Full Text
View/download PDF

42. Additional file 2: Figure S1. of Tumor treating fields (TTFields) delay DNA damage repair following radiation treatment of glioma cells

Author

Giladi, Moshe, Mijal Munster, Schneiderman, Rosa, Voloshin, Tali, Porat, Yaara, Blat, Roni, Zielinska-Chomej, Katarzyna, Hååg, Petra, Ze’ev Bomzon, Kirson, Eilon, Weinberg, Uri, Viktorsson, Kristina, Lewensohn, Rolf, and Palti, Yoram

Abstract

TTFields effect on LN-18 glioma cells. Surviving fractions of LN-18 cells treated with TTFields (200 kHz, 1.0 V/cm) for 72 h either alone or immediately after irradiation with 4 Gy (A). Surviving fraction of LN-18 cells treated with RT alone or with RT at various doses followed by 200 kHz TTFields (1.0 V/cm RMS) for 72 h. Results of the combined treatments were normalized to the effect of TTFields alone (B). (PPTX 2783 kb)

Published
2017
Full Text
View/download PDF

43. CBMT-29. INDUCTION OF AUTOPHAGY FOLLOWING TTFIELDS APPLICATION SERVES AS A SURVIVAL MECHANISM MEDIATED BY AMPK ACTIVATION

Author

Shteingauz, Anna, Porat, Yaara, Voloshin, Tali, Schneiderman, Rosa S, Munster, Mijal, Zeevi, Einav, Kaynan, Noa, Gotlib, Karnit, Giladi, Moshe, Kirson, Eilon, Weinberg, Uri, Kinzel, Adrian, and Plati, Yoram

Subjects
Abstracts, Cancer Research, Oncology, Neurology (clinical)
Abstract

Tumor treating fields (TTFields) are an approved treatment modality for patients with glioblastoma. Previous studies have shown that TTFields lead to increased cellular granularity, which is often associated with autophagy. In this study, we evaluated the effect of TTFields on the induction of autophagy in glioma cells. Cells were treated with TTFields using the inovitro system. Autophagy was monitored by quantifying levels of lipidated Microtubule Associated Protein Light Chain 3 (LC3-II) using immunoblotting and immunofluorescence microscopy. Transmission Electron Microscopy (TEM) was used to visualize autophagosome-like structures. Western blot analysis was utilized to evaluate autophagy regulatory activity of mTOR through p70 S6 kinase1 and AMPK and its down-stream target ULK-1. siRNAs was used to deplete siAMPK from U87-MG cells. To evaluate involvement of autophagy in cell fate after TTFields treatment, we produced glioma cell lines depleted from ATG7 by shATG7 infection. Significant elevation in LC3-II levels was observed in TTFields-treated cells using fluorescence microscopy; punctate distribution of LC3-II was observed. TEM micrographs demonstrated the presence of autophagy typical, autophagosome-like structures following TTFields treatment. Evidence of increased autophagic flux following TTFields treatment was detected using immunoblotting analysis in the presence of CQ. Western blot analysis of cells after TTFields treatment revealed the stimulation of AMPK signaling as well as activation of p70. Depletion of AMPK from U87-MG cells resulted in reduction of autophagy and enhancement of TTFields cytotoxicity. ER stress in treated cells was evident by immunoblotting, showing increased levels of ER stress marker GRP78. The combination of TTFields with CQ resulted in a significant dose-dependent reduction of cell growth compared with TTFields treatment alone. Cells with ATG7 depletion showed similar results. Combined, these results suggest that cells upregulate autophagy in response to ER stress induced by TTFields application and that AMPK may serve as a key regulator of this process.

Published
2018
Full Text
View/download PDF

44. ANGI-11. TUMOR TREATING FIELDS (TTFIELDS) INHIBIT CANCER CELL MIGRATION AND INVASION BY INDUCING REORGANIZATION OF THE ACTIN CYTOSKELETON AND FORMATION OF CELL ADHESIONS

Author

Schneiderman, Rosa S, primary, Giladi, Moshe, additional, Zeevi, Einav, additional, Voloshin, Tali, additional, Shteingauz, Anna, additional, Porat, Yaara, additional, Munster, Mijal, additional, Kirson, Eilon, additional, Weinberg, Uri, additional, and Palti, Yoram, additional

Published
2018
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results